<DOC>
	<DOC>NCT03048240</DOC>
	<brief_summary>The study pilot evaluate the feasibility of a "5-ALA- PpIX (protoporhyrin IX) mediated per-PDT protocol" in patients with glioblastoma accessible for complete surgical removal of contrast. This treatment will be carried out in addition to the current reference treatment of glioblastoma: maximum resection surgery followed by radiochemotherapy according to the protocol Stupp</brief_summary>
	<brief_title>INtraoperative photoDYnamic Therapy of GliOblastoma</brief_title>
	<detailed_description />
	<mesh_term>Glioblastoma</mesh_term>
	<criteria>1. Patient male or female ≥18 years 2. General status (WHO) of Performance status 0, 1 or 2 3. Probable glioblastoma according to clinical and radiological criteria, 4. whose surgical indication was given in Multidisciplinary consultation meeting (RCP) of neurooncology, 5. Decision to treat the patient as part of the Clinical trial also taken in neurooncology RCP ("Multidisciplinary consultation meeting") 6. Patient operable on the basis of absence of cardiopulmonary disease history; a complete medical checkup sufficient to insure a postoperative state with normal daily life 7. Clinical neurooncological monitoring and longterm MRI scheduled at the hospital CHRU of Lille, center of reference of the region 8. Patient able to understand and sign voluntarily Informed consent 9. Patient able to adhere to the visit's calendar of the study and other imperatives of the protocol 10. Women of childbearing potential should benefit of an effective contraception 11. For patients receiving hepatotoxic therapy in the long term, this treatment must be suspended during the 24h after taking 5ALA 12. Patient assigned to an heath insurance 1. Contraindications to 5ALA (Gliolan®) and to peroperative PhotoDynamic Therapy "perPDT": 2. Contraindications to 5ALA Porphyria Taking photosensitizer treatment Severe renal or hepatic impairment Bilirubin&gt; 1.5 x maximum level, Alkaline Phosphatases and transaminases (ASAT)&gt; 2.5 x Maximum. rates Creatinine clearance &lt;30 mL / min; Noncompliance with the rules of prevention of the transient risk of cutaneous photosensitization 3. Contraindications to surgery 4. Contraindications to magnetic resonance imaging (MRI) 5. Treatment with an experimental drug within 30 Days prior to the start of the study 6. Clinical followup impossible to perform for psychological, familial, social or geographical reasons, 7. Legal incapacity (persons deprived of their liberty or Guardianship or guardianship), 8. Pregnant or nursing women 9. Refusal to participate or sign the consent of the study 10. Soy allergy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Glioblastoma</keyword>
</DOC>